ConductScience.org, home

Comparison · NCT03403751-75306849

Reltecimod 0.5 mg/kg vs Placebo: Freedom From Durable Loss of Renal Function at Day 14

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Reltecimod 0.5 mg/kg vs Placebo: Freedom From Durable Loss of Renal Function at Day 14. Trial comparisons, record NCT03403751-75306849. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03403751-75306849

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.7140.5290.847wilson
Risk in group 20.7330.5560.858wilson
Risk difference, group 1 minus group 2-0.019-0.2420.203newcombe hybrid score
Risk ratio, group 1 over group 20.9740.7081.34log
Odds ratio, group 1 over group 20.9090.2872.88log
Number needed to treat, for one fewer participant with the outcome on Reltecimod 0.5 mg/kg than on Placebo52.5from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Reltecimod 0.5 mg/kgSingle IV infusion of 0.5 mg/kg Reltecimod (at a concentration of 1 mg/mL)2028OG000
Group 2PlaceboSingle IV infusion of 0.5 mL/kg of 0.9% sodium chloride (volume equivalent with Reltecimod dosing schema)2230OG001

Outcome

Type
SECONDARY
Title
Freedom From Durable Loss of Renal Function at Day 14
Description
Freedom from durable loss of renal function at Day 14 required all of the following 3 components: alive at Day 14, free of dialysis at Day 14, and less than 37% loss of estimated glomerular filtration rate (eGFR) at Day 14 from patient reference eGFR (measured by Modification of Diet in Renal Disease \[MDRD\] formula).
Time frame
14 Days
Population
This analysis population (modified intent-to-treat \[mITT\]) included all randomized patients who were exposed to study drug (reltecimod or placebo) and who had a suspected or confirmed diagnosis of abdominal sepsis or confirmed NSTI and Stage 2 or Stage 3 AKI, with patients analyzed according to the treatment actually received.

Source ClinicalTrials.gov

Trial

Title
Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury
NCT number
NCT03403751
Phases
PHASE3
Conditions
Acute Kidney Injury, Peritonitis, Necrotizing Soft Tissue Infection
Interventions
Reltecimod 0.5 mg/kg, Placebo
Lead sponsor
Atox Bio Ltd
Results first posted
2021-09-16

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03403751-75306849